You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

carfilzomib

Showing 1 - 25 of 154
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in Detroit, Charlotte (Carfilzomib, Ruxolitinib, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Detroit, Michigan
  • +1 more
Jan 27, 2023

Multiple Myeloma Trial in West Hollywood, Cary (Selinexor, Placebo (for selinexor), carfilzomib)

Withdrawn
  • Multiple Myeloma
  • West Hollywood, California
  • +1 more
Jan 24, 2023

Multiple Myeloma Trial in Beverly Hills (Elranatamab, Carfilzomib)

Recruiting
  • Multiple Myeloma
  • Beverly Hills, California
    Beverly Hills Cancer Center
Dec 21, 2022

Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • (no location specified)
Feb 3, 2023

Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Chicago, Illinois
    University of Chicago Medicine Comprehensive Cancer Center
Mar 23, 2023

Multiple Myeloma Trial in United States (Isatuximab, Carfilzomib, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • San Francisco, California
  • +3 more
Dec 24, 2022

Waldenstrom Macroglobulinemia Trial in Hackensack (Carfilzomib, Rituximab, Dexamethasone)

Completed
Has Results
  • Waldenstrom Macroglobulinemia
  • Carfilzomib
  • +2 more
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Mar 18, 2022

Carfilzomib in Patients With Multiple Myeloma

Recruiting
  • Multiple Myeloma
  • Carfilzomib
  • Odense, Denmark
    Odense University Hospital
Dec 20, 2022

Kyprolis® in Combination With Revlimid® and Dexamethasone or

Recruiting
  • Multiple Myeloma in Relapse
  • Carfilzomib
  • Frankfurt, Germany
    Centrum für Hämatologie und Onkologie Bethanien
Jun 2, 2022

Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Poitiers (Isatuximab, Carfilzomib, Pomalidomide)

Active, not recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Poitiers, France
    CHU Poitiers
Jan 9, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jun 14, 2022

Multiple Myeloma Trial in Torino (Carfilzomib, Cyclophosphamide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Torino, Italy
    Fondazione EMN Italy Onlus
Mar 24, 2022

Multiple Myeloma Trial in New York (carfilzomib, Dexamethasone, Clarithromycin)

Active, not recruiting
Has Results
  • Multiple Myeloma
  • carfilzomib
  • +3 more
  • New York, New York
    Weill Cornell Medical College
Apr 10, 2022

Multiple Myeloma Trial in Torino (Carfilzomib, Cyclophosphamide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Torino, Italy
    Fondazione EMN Italy Onlus
Mar 24, 2022

Multiple Myeloma Trial in Torino (Carfilzomib, Pomalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Carfilzomib
  • +2 more
  • Torino, Italy
    Dipartimento di Biotecnologie Molecolari e Scienze per la Salute
Mar 24, 2022

Hematologic Malignancies, Relapse, GVHD Trial in Ann Arbor (Carfilzomib, Tacrolimus)

Completed
Has Results
  • Hematologic Malignancies
  • +2 more
  • Ann Arbor, Michigan
    University of Michigan Hospital
Dec 3, 2021

Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma Trial in Canada, United States (drug, procedure,

Active, not recruiting
Has Results
  • Stage I Multiple Myeloma
  • +2 more
  • Chicago, Illinois
  • +4 more
Sep 3, 2022

Neuroendocrine Cancer Trial in United States (Carfilzomib)

Completed
Has Results
  • Neuroendocrine Cancer
  • Carfilzomib
  • Denver, Colorado
  • +9 more
Jun 7, 2022

Plasma Cell Myeloma Trial in Atlanta (Carfilzomib, Dexamethasone, Pomalidomide)

Recruiting
  • Plasma Cell Myeloma
  • Carfilzomib
  • +2 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Oct 5, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Carfilzomib
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • Carfilzomib
  • +2 more
  • (no location specified)
Aug 8, 2022

Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse Trial in Boston (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +3 more
  • Boston, Massachusetts
  • +2 more
Oct 28, 2021

Multiple Myeloma Trial in Washington, Hackensack (Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG)

Recruiting
  • Multiple Myeloma
  • Selinexor 60 MG
  • +6 more
  • Washington, District of Columbia
  • +1 more
Feb 3, 2022

Refractory Multiple Myeloma Trial in United States (selinexor, carfilzomib, dexamethasone)

Recruiting
  • Refractory Multiple Myeloma
  • Scottsdale, Arizona
  • +4 more
Apr 1, 2022